Moderate to Severe Binge Eating Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Moderate to Severe Binge Eating Disorder Market Outlook

Thelansis’s “Moderate to Severe Binge Eating Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Binge Eating Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Moderate to Severe Binge Eating Disorder Overview

Binge Eating Disorder (BED) is defined as an eating disorder marked by repetitive instances of binge eating, during which the person consumes more food than would typically be consumed within a distinct timeframe. Binge eating disorder (BED) is closely related to non-purging bulimia nervosa (BN), although there are distinctions between the two. The key characteristics of BED involve engaging in episodes of binge eating, occurring at least twice a week for six months, and accompanied by considerable distress. Unlike nonpurging bulimia nervosa, BED does not involve compensatory actions to avoid weight gain, such as self-induced vomiting, laxative or diuretic use, or other medications. While many individuals with BED are overweight, not all fall into this category. Overweight individuals with BED are subject to the typical health risks of obesity, such as diabetes, hypertension, and orthopedic issues. The binge-eating disorder commonly emerges as an outcome or consequence of depression. Individuals often resort to "comfort foods" to cope with their depressive feelings. The development of binge-eating disorder, similar to anorexia nervosa or bulimia nervosa, may initiate from low self-esteem or self-image. This disorder tends to arise when attempts to enhance self-assurance prove unsuccessful or go unrecognized externally. Faulty internal communication can also contribute to the development of binge-eating disorder. Factors that contribute to the emergence of this disorder include severe childhood obesity, a family history of overeating, experiences of body-related bullying or teasing, and substance abuse such as drugs or alcohol. Binge-eating disorder is most frequently identified in individuals who are overweight or obese. Current diagnostic criteria necessitate the occurrence of at least one binge episode per week for a duration of three months. Individuals grappling with binge-eating disorder are at an elevated risk of encountering depression and substance misuse. The treatment of binge-eating disorder in adults has succeeded through a combination of cognitive-behavioral therapy and antidepressant medication. BED is the most prevalent eating disorder in both the United States and Europe, with higher occurrences observed among teenagers and young adults. On average, the onset of BED occurs around the age of 25.

• The prevalence of BED in children globally stands at 0.7%. In males, the one-year prevalence of BED is 0.26%, with the highest prevalence (0.48%) occurring in males aged 10-19. Among women, the age group of 20-29 exhibits the highest BED prevalence rates, estimated at 2.09%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: